Artelo Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Artelo Biosciences, Inc. carries a market capitalization of 3.41M, placing it among publicly traded companies globally. Its enterprise value stands at -6.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.41M |
| Enterprise Value | -6.54M |
Share Statistics
Artelo Biosciences, Inc. currently has 876,032.00 shares outstanding.
| Shares Outstanding | 876,032.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | -0.37 |
| P/OCF Ratio | -0.37 |
Financial Position
Artelo Biosciences, Inc. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.78, indicating elevated leverage, while an interest coverage ratio of -29.21 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.79 |
| Quick Ratio | 1.76 |
| Debt / Equity | 10.78 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -29.21 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -167.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Artelo Biosciences, Inc.'s stock has declined approximately -77.25857% over the past 52 weeks. The 50-day moving average sits at 4.03, while the 200-day moving average is 8.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -77.25857% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 8.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.71M, while operating income came in at -11.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.71M |
| Pretax Income | -13.46M |
| Net Income | -13.46M |
| EBITDA | -11.71M |
| EBIT | -11.71M |
| Earnings Per Share (EPS) | -33.87 |
Balance Sheet
Artelo Biosciences, Inc. holds 10.27M in cash and equivalents against 719,000.00 in total debt, resulting in a net debt position of -9.61M. Total book value stands at -65.97M, with working capital of 4.59M providing operational flexibility.
| Cash & Cash Equivalents | 10.27M |
| Total Debt | 719,000.00 |
| Net Debt | -9.61M |
| Equity (Book Value) | -65.97M |
| Book Value Per Share | -165.94 |
| Working Capital | 4.59M |
Cash Flow
Artelo Biosciences, Inc. produced -8.11M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.11M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.11M |
| FCF Per Share | -20.41 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -588.26 |
| FCF Yield | -269.26 |
Stock Splits
Artelo Biosciences, Inc.'s most recent stock split took place on March 10, 2026 with a 3:1 split ratio.
| Last Split Date | 3/10/2026 |
| Split Ratio | 3:1 |
Scores
Artelo Biosciences, Inc. posts an Altman Z-Score of -11.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.67 |